Literature DB >> 24462067

Meta-analysis of the quantitative relation between pulse pressure and mean arterial pressure and cardiovascular risk in patients with diabetes mellitus.

Satoru Kodama1, Chika Horikawa2, Kazuya Fujihara3, Sakiko Yoshizawa2, Yoko Yachi4, Shiro Tanaka5, Nobumasa Ohara2, Satoshi Matsunaga2, Takaho Yamada2, Osamu Hanyu2, Hirohito Sone6.   

Abstract

Results of epidemiologic studies that investigated the significance of pulse pressure (PP) and mean arterial pressure (MAP) in terms of risk of cardiovascular disease (CVD) in patients with diabetes mellitus are inconsistent. We performed a quantitative meta-analysis to estimate CVD risk in relation to PP or MAP. Electronic literature search was conducted for prospective studies providing data on CVD risk for an increment in baseline MAP or PP in patients with diabetes mellitus. The pooled CVD risk for a 10-mm Hg increase in each blood pressure (BP) index was estimated with a random-effects model. There were 17 eligible studies consisting of 52,647 patients and 5,112 CVD cases. The pooled relative risk (95% confidence interval) of CVD for an increment of 10 mm Hg was 1.10 (1.04 to 1.16) for PP and 1.09 (0.98 to 1.21) for MAP. Significant between-study heterogeneity was observed (I(2) [p value]; 76.5% [p <0.001] for PP, 67.8% [p = 0.005] for MAP). In studies concurrently investigating CVD risk for the 4 indexes (i.e., PP, MAP, systolic BP, and diastolic BP), the pooled relative risk (95% confidence interval) was 1.17 (1.09 to 1.26) for PP, 1.11 (1.06 to 1.15) for MAP, 1.14 (1.06 to 1.22) for systolic BP, and 1.06 (0.94 to 1.19) for diastolic BP. In conclusion, the current meta-analysis suggested that PP was the strongest indicator among the 4 commonly used BP indexes. However, the large heterogeneity urged cautious interpretation of the study results.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24462067     DOI: 10.1016/j.amjcard.2013.12.005

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

1.  Atazanavir improves cardiometabolic measures but not vascular function in patients with long-standing type 1 diabetes mellitus.

Authors:  Jessica Milian; Allison B Goldfine; Jonah P Zuflacht; Caitlin Parmer; Joshua A Beckman
Journal:  Acta Diabetol       Date:  2015-01-08       Impact factor: 4.280

2.  Association Between Admission Pulse Pressure and Long-Term Mortality in Elderly Patients With Type 2 Diabetes Mellitus Admitted for Acute Coronary Syndrome: An Observational Cohort Study.

Authors:  Zijian Wang; Xiaoran Li; Yichun Wang; Boyi Bao; Xiaosong Ding; Hongwei Li; Weiping Li
Journal:  Front Cardiovasc Med       Date:  2022-05-11

Review 3.  Impact of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging-What Do We Know So Far? (A Narrative Review).

Authors:  Cristina Andreea Adam; Razvan Anghel; Dragos Traian Marius Marcu; Ovidiu Mitu; Mihai Roca; Florin Mitu
Journal:  Life (Basel)       Date:  2022-05-27

4.  Prognostic Significance of Pulse Pressure and Other Blood Pressure Components for Coronary Artery Disease in Type 1 Diabetes.

Authors:  Jingchuan Guo; Matthew F Muldoon; Maria M Brooks; Trevor J Orchard; Tina Costacou
Journal:  Am J Hypertens       Date:  2019-10-16       Impact factor: 3.080

Review 5.  Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin.

Authors:  Vani P Sanon; Shalin Patel; Saurabh Sanon; Ruben Rodriguez; Son V Pham; Robert Chilton
Journal:  Ther Clin Risk Manag       Date:  2017-05-03       Impact factor: 2.423

Review 6.  Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.

Authors:  Matthew J Budoff; John P H Wilding
Journal:  Int J Clin Pract       Date:  2017-05       Impact factor: 2.503

7.  Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.

Authors:  Michael Pfeifer; Raymond R Townsend; Michael J Davies; Ujjwala Vijapurkar; Jimmy Ren
Journal:  Cardiovasc Diabetol       Date:  2017-02-27       Impact factor: 9.951

8.  Interaction between Mean Arterial Pressure and HbA1c in Prediction of Cardiovascular Disease Hospitalisation: A Population-Based Case-Control Study.

Authors:  Dahai Yu; Zhanzheng Zhao; David Simmons
Journal:  J Diabetes Res       Date:  2016-06-13       Impact factor: 4.011

9.  Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride.

Authors:  Kyeong Seon Park; SooHeon Kwak; Young Min Cho; Kyong Soo Park; Hak C Jang; Seong Yeon Kim; Hye Seung Jung
Journal:  J Diabetes Investig       Date:  2016-10-12       Impact factor: 4.232

10.  Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.

Authors:  R Chilton; I Tikkanen; C P Cannon; S Crowe; H J Woerle; U C Broedl; O E Johansen
Journal:  Diabetes Obes Metab       Date:  2015-10-09       Impact factor: 6.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.